 Connection
Michael Verneris to Neoplasms
This is a "connection" page, showing publications Michael Verneris has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.529 |
|
|
|
-
Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013 May; 28(4):274-82.
Score: 0.166
-
Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022 09 13; 6(17):5222-5226.
Score: 0.079
-
Mar?n-Jim?nez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021; 12:607282.
Score: 0.072
-
Lu H, Bhoopatiraju S, Wang H, Schmitz NP, Wang X, Freeman MJ, Forster CL, Verneris MR, Linden MA, Hallstrom TC. Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. Oncotarget. 2016 Nov 15; 7(46):76047-76061.
Score: 0.053
-
Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J. 2015 Nov-Dec; 21(6):486-91.
Score: 0.049
-
Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014 Apr; 26(2):161-72.
Score: 0.044
-
Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer. 2010 Jan; 54(1):138-43.
Score: 0.033
-
Grupp SA, Verneris M, Sondel PM, Cooper LJ. Immunotherapy for pediatric cancer. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):33-43.
Score: 0.029
-
Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001 May 15; 97(10):2923-31.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|